Brain Surgery (Craniotomy) — Cost, Top Hospitals & Success Rates | MyMedicPlus

Brain surgery, in its most common form, involves a craniotomy — the surgical removal of a section of skull bone (the bone flap) to gain access to the brain and its surrounding structures. At the conclusion of the procedure, the bone flap is replaced and fixed with titanium plates and screws, restoring the cranial vault. When the bone flap is deliberately not replaced — for example to allow the brain to swell after traumatic brain injury or large hemispheric stroke — the procedure is called a craniectomy, with cranioplasty (bone replacement) performed weeks to months later once swelling has resolved.

Craniotomy is among the oldest and most technically demanding operations in surgery. The modern era, from the 1990s onwards, has been transformed by frameless stereotactic neuronavigation, intraoperative neurophysiology monitoring, advanced neuroanesthesia, and, more recently, intraoperative imaging and fluorescence-guided tumour resection. These technologies have dramatically improved the precision of intracranial surgery, enabling more complete tumour removal with less injury to surrounding eloquent brain tissue.

Brain surgery is performed by consultant neurosurgeons supported by specialist neuroanaesthetists, scrub nurses and surgical technicians with neurosurgical training, intraoperative neurophysiology technicians, and in many centres a neuronavigation specialist or radiographer. The operating theatre is equipped with a microscope, neuronavigation workstation, bipolar diathermy, ultrasonic aspirators, and increasingly an intraoperative MRI (iMRI) suite.

The decision to proceed with craniotomy is made after comprehensive assessment including clinical history, neurological examination, advanced neuroimaging (MRI brain with and without contrast, functional MRI, diffusion tensor imaging tractography for eloquent area mapping), and discussion at a specialist multidisciplinary team (MDT) meeting involving neurosurgery, neuroradiology, neuropathology, neuro-oncology, and radiation oncology.

Craniotomy is indicated across a wide range of intracranial pathologies:

• Primary brain tumours — Gliomas: The most common indication for elective craniotomy. The 2021 WHO Classification of Central Nervous System Tumours stratifies gliomas by IDH mutation status, MGMT promoter methylation, and 1p/19q codeletion. High-grade gliomas (glioblastoma IDH-wildtype, grade 4) require maximum safe resection, as extent of resection correlates with survival. MGMT methylation predicts benefit from temozolomide chemotherapy following surgery and radiotherapy.
• Meningiomas: Typically benign (WHO Grade 1) tumours arising from the meninges. Symptomatic or growing meningiomas in accessible locations are resected by craniotomy. Simpson Grade I resection (complete removal with overlying dura and affected bone) achieves the lowest recurrence rates.
• Brain Metastases: Surgical resection is appropriate for single or oligo-metastases in accessible locations, in patients with good performance status and controlled systemic disease. Surgery provides histological confirmation and local control, often followed by stereotactic radiosurgery to the resection cavity.
• Arteriovenous Malformations (AVMs): Unruptured and ruptured AVMs may be treated by microsurgical resection (craniotomy), endovascular embolisation, stereotactic radiosurgery, or a combination depending on Spetzler-Martin grade and angioarchitecture.
• Cerebral Abscess: Surgical drainage by craniotomy or stereotactic aspiration, with prolonged targeted antibiotic therapy guided by microbiological culture.
• Traumatic and Spontaneous Haematomas: Acute extradural haematomas (EDH) with significant volume or neurological deterioration require emergency craniotomy for haematoma evacuation. Selected intracerebral haematomas may be evacuated by craniotomy, stereotactic aspiration, or minimally invasive techniques.
• Epilepsy Surgery: Resection of epileptogenic foci (temporal lobectomy, lesionectomy, or hemispherectomy) after comprehensive pre-surgical evaluation including video-EEG telemetry, fMRI language lateralisation, and Wada test.

Patient selection for craniotomy requires careful balancing of the surgical goal (tumour removal, haematoma evacuation, epilepsy control) against operative risk, which depends on lesion characteristics, patient factors, and surgeon expertise.

Key eligibility considerations include:

• Performance status: The Karnofsky Performance Scale (KPS) is used in neuro-oncology. A KPS of 70 or above (patient able to care for self) generally supports surgical candidacy. Lower performance status increases perioperative mortality and complication risk and may shift the risk-benefit balance towards biopsy or non-surgical management.
• Lesion location and eloquence: Tumours and lesions in eloquent areas — primary motor cortex, language areas (Broca's and Wernicke's), primary visual cortex, brainstem, and deep subcortical structures — carry higher surgical risk of new neurological deficits. Awake craniotomy allows real-time cortical mapping in conscious patients to preserve eloquent function during resection of nearby lesions.
• Lesion accessibility: Superficial, convexity, and temporal lesions carry the lowest operative risk. Deep-seated lesions (basal ganglia, thalamus, posterior fossa) carry higher morbidity and may be better approached by stereotactic biopsy or radiosurgery.
• Medical comorbidities: Severe cardiac disease, coagulopathy, active systemic infection, and poor nutritional status all increase operative risk and may require optimisation or exclusion from surgery.
• Patient consent and values: Informed consent must include frank discussion of the specific risks of neurological deficit, infection, haemorrhage, and anaesthesia, as well as the realistic expected benefit. Some patients, particularly with high-grade glioma, may prioritise quality of life over tumour control when informed of the likely outcomes.

All surgical candidates should be discussed at a neuro-oncology or neurovascular MDT before proceeding, with input from neuroradiology, neuropathology, radiation oncology, and neurology.

Frameless Stereotactic Neuronavigation: Preoperative MRI and CT data are registered to the patient's head position in the operating theatre using surface landmarks or fiducial markers. Systems such as BrainLab Kick and Stryker Spine Navigation provide real-time 3D anatomical guidance, allowing the surgeon to plan the optimal craniotomy size, approach trajectory, and tumour boundary before making incision. Navigation accuracy is typically within 1–2 mm but degrades as brain shift occurs during surgery (so-called brain-shift error), limiting reliance on navigation for deep tumour margins.

Awake Craniotomy with Cortical Mapping: Performed under conscious sedation with local scalp anaesthesia or with general anaesthesia for the opening and closing phases and awake for the resection phase. The conscious patient performs specific tasks — naming objects, counting, moving limbs — while the surgeon applies electrical cortical and subcortical stimulation to map eloquent areas. This real-time functional mapping allows resection of tumours within or adjacent to language and motor areas with a significantly lower rate of permanent deficit than surgery under general anaesthesia alone.

5-ALA Fluorescence-Guided Tumour Resection: 5-aminolevulinic acid (5-ALA, trade name Gliolan) is administered orally 3 hours before surgery. It is selectively metabolised by high-grade glioma cells to protoporphyrin IX, which fluoresces pink-red under blue-violet light via the operative microscope. The pivotal randomised trial by Stummer et al. (Lancet Oncology 2006) demonstrated that 5-ALA-guided resection achieved complete tumour removal (no residual contrast enhancement on MRI) in 65% of patients versus 36% in the white-light control group, with significantly longer 6-month progression-free survival. 5-ALA resection is now standard of care for glioblastoma surgery in Europe and is licensed by the FDA in the US.

Intraoperative MRI (iMRI): A randomised controlled trial by Senft et al. (Lancet Oncology 2011, N=58 glioma patients) demonstrated that iMRI-guided surgery achieved complete resection in 96% versus 68% in the conventional group, with no increase in neurological morbidity. iMRI allows real-time assessment of residual tumour during the operation, enabling the surgeon to re-inspect and extend resection where safe before wound closure. iMRI suites require substantial capital investment and are currently available in specialist neurosurgical centres.

Keyhole Craniotomy Approaches: Minimally invasive approaches — including the supraorbital (eyebrow) craniotomy for anterior skull base lesions and the retrosigmoid craniotomy for posterior fossa tumours — limit the size of the skull opening, reducing scalp dissection, blood loss, and hospital stay while maintaining adequate surgical access. Intraoperative ultrasound complements navigation in keyhole surgery by providing real-time subsurface imaging without the cost and space requirements of iMRI.

Surgical Prophylaxis: Cefazolin 1–2g IV (or clindamycin in beta-lactam allergy) is administered within 60 minutes of skin incision for surgical site infection (SSI) prophylaxis. VTE prophylaxis with mechanical compression devices is applied intraoperatively; low-molecular-weight heparin is initiated 24–48 hours postoperatively once haemostasis is confirmed.

Craniotomy offers distinct benefits depending on the underlying pathology:

• Histological diagnosis: For suspected brain tumours, craniotomy (or stereotactic biopsy) is the only definitive way to obtain tissue for histopathological diagnosis, WHO grade classification, and molecular profiling (IDH, MGMT, 1p/19q). Without accurate diagnosis, oncological treatment — chemotherapy and radiotherapy — cannot be optimally planned.
• Maximum safe resection in glioma: Extent of resection (EOR) is an independent prognostic factor in glioblastoma and lower-grade gliomas. Multiple observational studies and meta-analyses support the association between greater EOR and improved overall survival. The use of 5-ALA and iMRI has increased rates of complete contrast-enhancing tumour resection from approximately 35–40% to 65–96% at specialist centres, with meaningful survival benefits.
• Symptom relief and steroid reduction: Tumour debulking reduces mass effect and perilesional vasogenic oedema, leading to improvements in headache, seizure frequency, and focal neurological deficits. Successful resection typically allows rapid reduction or cessation of dexamethasone, with the associated reduction in steroid side effects (hyperglycaemia, immunosuppression, proximal myopathy, insomnia).
• Emergency haematoma evacuation: In acute extradural haematoma with haemodynamic decline or pupillary changes, emergency craniotomy and haematoma evacuation is life-saving. Outcome is directly related to speed of surgical intervention — the concept of talk and die underlines the risk of apparently lucid patients deteriorating rapidly without surgery.
• Seizure freedom in epilepsy surgery: For carefully selected patients with drug-resistant focal epilepsy and a resectable seizure focus, surgery achieves seizure freedom (Engel Class I) in approximately 60–70% at 1 year for temporal lobe epilepsy (mesial temporal sclerosis) and 50–60% for extra-temporal lesional epilepsy.

Brain surgery carries significant risks that must be discussed in detail with patients and families before consent is obtained. The specific risk profile depends on the lesion location, complexity, and patient factors:

• New neurological deficits: The most feared surgical complication. Depending on tumour location and surgical approach, new or worsening motor weakness, speech or language disturbance, visual field defect, cognitive impairment, or personality change may occur. The risk of permanent new deficit ranges from less than 5% for accessible convexity lesions in non-eloquent areas to 20–30% for eloquent area tumours. Awake craniotomy with cortical mapping reduces the risk of permanent deficit by approximately half compared to asleep surgery for eloquent area tumours.
• Postoperative haematoma: Intracerebral, extradural, or subdural haematoma occurs in 2–5% of craniotomies and may require immediate return to theatre. Risk is higher in patients taking antiplatelet agents or anticoagulants at the time of surgery.
• Surgical site infection (SSI): Superficial wound infection occurs in 1–3% and deep infection (meningitis, cerebral abscess, bone flap osteitis) in 1–2% of craniotomies, despite prophylactic antibiotics. Deep infection may require bone flap removal and prolonged intravenous antibiotic treatment.
• Cerebrospinal fluid (CSF) leak: Inadequate dural closure may lead to CSF leaking through the wound (CSF fistula) or accumulating under the scalp (pseudomeningocele), with risk of ascending meningitis. Most CSF leaks are managed with lumbar drainage or repeat surgical exploration.
• Venous thromboembolism (VTE): Neurosurgical patients are at particularly high VTE risk due to immobility, prolonged surgery, and tumour-related hypercoagulability. Pulmonary embolism is a leading cause of postoperative death in neurosurgical patients; mechanical compression and carefully timed pharmacological prophylaxis are mandatory.
• Postoperative seizures: Craniotomy itself is a seizure risk factor due to cortical irritation. Antiseizure medication (typically levetiracetam) is routinely used perioperatively. New-onset seizures require neurological assessment and may necessitate long-term antiseizure treatment.

Immediate postoperative care: Most patients are monitored overnight in a neurosurgical HDU or NCCU. Early postoperative MRI (within 24–48 hours of surgery, ideally within 72 hours for oncological cases) provides baseline imaging for comparison and documents the extent of resection before postoperative enhancement from blood-brain barrier disruption obscures residual tumour.

Neurological rehabilitation: Physiotherapy, occupational therapy, and speech therapy assessment occurs within 24–48 hours of surgery for patients with new or pre-existing neurological deficits. The sooner rehabilitation begins, the better the neurological recovery trajectory.

Wound and steroid management: Skin sutures or clips are removed at 10–14 days. Dexamethasone is tapered according to symptoms over 1–4 weeks post-discharge; prolonged high-dose steroid use causes diabetes, infection, proximal myopathy, and adrenal suppression.

Neuro-oncology follow-up: For malignant brain tumours, oncological treatment — concurrent temozolomide chemotherapy and radiotherapy (Stupp protocol for glioblastoma) — typically commences 4–6 weeks after surgery. Regular MRI surveillance at 8–12 weekly intervals monitors for tumour progression, treatment response (Macdonald or RANO criteria), and pseudoprogression (treatment-related changes mimicking tumour growth).

Epilepsy surgery follow-up: Antiseizure medications are gradually weaned over 1–2 years in seizure-free patients after temporal lobectomy. Driving licence restrictions apply following craniotomy in most jurisdictions (typically 6–12 months seizure-free before driving is permitted).

Long-term surveillance: Meningioma patients require MRI surveillance every 2–5 years depending on WHO grade and extent of resection. Glioma patients require regular imaging and oncological review for the duration of treatment and survivorship.

Brain surgery is one of the most costly surgical interventions, reflecting the complexity of the procedure, duration of surgery, and sophisticated technology involved. Cost awareness is important for international medical travellers and for patients comparing treatment options.

• Procedure complexity and duration: A straightforward temporal lobectomy for epilepsy or meningioma resection may take 3–5 hours; an awake craniotomy for eloquent area glioma may take 6–10 hours. Operating time is the primary driver of theatre cost, with each additional hour adding USD 1,500–3,000 in high-income settings.
• Navigation and fluorescence technology: Centres using frameless neuronavigation, 5-ALA fluorescence, and iMRI typically apply technology surcharges of USD 3,000–10,000 per case in the US and EUR 2,000–6,000 in Europe. At specialist Indian centres, these technologies are available at a fraction of the cost.
• Anaesthesia for awake craniotomy: Awake craniotomy with neuropsychological intraoperative testing requires a highly skilled neuroanaesthetic team and longer theatre time, adding approximately USD 2,000–5,000 to procedure costs compared to conventional general anaesthesia craniotomy.
• Total costs by country: In the United States, craniotomy for brain tumour resection typically costs USD 50,000–200,000 including hospitalisation, surgeon fees, anaesthesia, imaging, and intensive care. In the United Kingdom, NHS costs are borne by the health service; private sector costs range from GBP 20,000–80,000. At JCI-accredited neurosurgical centres in India (e.g. Medanta, Apollo, Manipal), equivalent procedures cost USD 8,000–25,000, including hospital stay, surgery, and post-operative monitoring.
• Post-operative oncological treatment: For glioblastoma, the Stupp protocol of 6 weeks of concurrent radiotherapy plus daily temozolomide, followed by 6 monthly cycles of adjuvant temozolomide, adds USD 30,000–80,000 in the US, with dramatically lower costs in countries with robust generic chemotherapy supply.

For selected patients or lesions, alternatives to open craniotomy offer equivalent or acceptable outcomes with lower surgical morbidity:

• Stereotactic Radiosurgery (SRS): High-dose, precisely focused radiation delivered in a single fraction or few fractions using Gamma Knife (cobalt-60 sources), CyberKnife (linear accelerator on a robotic arm), or LINAC-based SRS. SRS achieves local control rates of 90–95% for brain metastases up to 3–4 cm, 90–95% for acoustic neuromas, and 80–90% for WHO Grade I meningiomas — without surgical incision. SRS is the primary treatment for multiple brain metastases, residual or recurrent meningiomas, and small acoustic neuromas where hearing preservation is desired.
• Stereotactic Biopsy: When histological diagnosis is required from a deep or eloquent location where open resection would carry prohibitive morbidity, stereotactic needle biopsy using a frame-based or frameless system can safely obtain diagnostic tissue. Diagnostic yield exceeds 95% for adequate specimens; haemorrhage risk is approximately 1–2%. Stereotactic biopsy alone does not provide the survival benefit of resection in glioblastoma but is appropriate when resection is not feasible or not desired.
• Medical management of vasogenic oedema: For patients with incidental small meningiomas or low-grade gliomas without significant mass effect or symptoms, dexamethasone controls peri-tumoral oedema and symptom burden while a watchful waiting approach is adopted. Serial MRI surveillance monitors for growth requiring intervention.
• Endovascular treatment for AVMs: Endovascular embolisation of cerebral arteriovenous malformations, using Onyx or n-BCA liquid embolic agents, reduces AVM nidus volume and can render smaller AVMs amenable to curative SRS or reduce intraoperative bleeding at subsequent microsurgical resection.